FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

View source ↗

Summary

FDA approves a higher-dose 7.2 mg Wegovy (semaglutide) injection for weight loss and maintenance in certain adults under the National Priority Voucher program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• WEGOVY (Semaglutide)

Snippet

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.